Published in Vet Immunol Immunopathol on May 01, 1982
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol (2000) 2.60
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci (2002) 2.18
Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J (1999) 2.07
Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem (1998) 1.97
Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer (1991) 1.77
Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res (1996) 1.74
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res (1999) 1.72
Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia (1994) 1.69
MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A (1999) 1.59
The glycosaminoglycan content of renal basement membranes in the congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol (1992) 1.55
Elastin as a biomaterial for tissue engineering. Biomaterials (2007) 1.53
A radiochemical procedure for the assay of fatty acid binding by proteins. Anal Biochem (1983) 1.52
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer (1999) 1.50
Three-dimensional structure of recombinant human muscle fatty acid-binding protein. J Biol Chem (1992) 1.49
A mitochondrial encephalomyopathy: the first case with an established defect at the level of coenzyme Q. Eur J Pediatr (1986) 1.46
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol (1999) 1.43
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol (2000) 1.40
Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry (2000) 1.39
Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res (1999) 1.38
Intracellular fatty acid-binding proteins. Int J Biochem (1985) 1.36
Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J (1992) 1.35
Fatty acid composition of Bifidobacterium and Lactobacillus strains. J Bacteriol (1971) 1.35
Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res (1986) 1.33
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol (1993) 1.32
Structural studies on human muscle fatty acid binding protein at 1.4 A resolution: binding interactions with three C18 fatty acids. Structure (1994) 1.29
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ (2013) 1.27
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res (2000) 1.26
Elimination of autofluorescence in immunofluorescence microscopy with digital image processing. J Histochem Cytochem (1995) 1.25
Preparation and characterization of porous crosslinked collagenous matrices containing bioavailable chondroitin sulphate. Biomaterials (1999) 1.25
Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res (2002) 1.23
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol (2004) 1.23
14CO2 production is no adequate measure of [14C]fatty acid oxidation. Biochem Med Metab Biol (1986) 1.22
Linkage of chondroitin-sulfate to type I collagen scaffolds stimulates the bioactivity of seeded chondrocytes in vitro. Biomaterials (2001) 1.22
Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res (2000) 1.21
Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J (1991) 1.20
Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta (1988) 1.20
Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood (1999) 1.20
Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem (1998) 1.20
A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int (1992) 1.19
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer (1999) 1.19
Development of tailor-made collagen-glycosaminoglycan matrices: EDC/NHS crosslinking, and ultrastructural aspects. Biomaterials (2000) 1.18
Leigh's encephalomyelopathy in a patient with cytochrome c oxidase deficiency in muscle tissue. Pediatrics (1977) 1.18
Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J Neurosci (2000) 1.16
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res (2001) 1.14
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol (1994) 1.14
Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. J Autoimmun (1990) 1.14
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer (2003) 1.12
Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin Chim Acta (1985) 1.11
Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol (1995) 1.11
The activity state of the branched-chain 2-oxo acid dehydrogenase complex in rat tissues. Biochem J (1984) 1.11
The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol (2001) 1.11
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res (1994) 1.10
Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia (2000) 1.10
Ligand specificity and conformational stability of human fatty acid-binding proteins. Int J Biochem Cell Biol (2001) 1.09
Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology (1999) 1.09
Pyruvate oxidation in rat and human skeletal muscle mitochondria. Biochem Med (1978) 1.09
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer (2002) 1.09
Diurnal variation of cytosolic fatty acid-binding protein content and of palmitate oxidation in rat liver and heart. J Biol Chem (1984) 1.08
Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol (2012) 1.08
Investigation of mitochondrial metabolism in small human skeletal muscle biopsy specimens. Improvement of preparation procedure. Clin Chim Acta (1985) 1.08
A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem (1998) 1.08
Differentiation markers of mouse C2C12 and rat L6 myogenic cell lines and the effect of the differentiation medium. In Vitro Cell Dev Biol Anim (1999) 1.07
Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int (1993) 1.07
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol (2009) 1.07
The effect of malonyl-CoA on fatty acid oxidation in rat muscle and liver mitochondria. Biochim Biophys Acta (1982) 1.06
Reproducible gene expression measurement among multiple laboratories obtained in a blinded study using standardized RT (StaRT)-PCR. Mol Diagn (2001) 1.06
Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus (2004) 1.06
Incomplete palmitate oxidation in cell-free systems of rat and human muscles. Biochim Biophys Acta (1983) 1.05
mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia (2000) 1.05
Effect of genetic variants of the heart fatty acid-binding protein gene on intramuscular fat and performance traits in pigs. J Anim Sci (1999) 1.04
Combination chemotherapy studies with gemcitabine. Semin Oncol (1997) 1.04
Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer (1998) 1.04
Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A-silver staining in agarose gels. Anal Biochem (1994) 1.04
Fatty-acid-binding proteins do not protect against induced cytotoxicity in a kidney cell model. Biochem J (2001) 1.03
Effect of starvation and exercise on actual and total activity of the branched-chain 2-oxo acid dehydrogenase complex in rat tissues. Biochem J (1984) 1.03
Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur J Cancer (2003) 1.02
End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res (2001) 1.02
Characterization and binding properties of fatty acid-binding proteins from human, pig, and rat heart. Arch Biochem Biophys (1988) 1.02
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer (2000) 1.02
Members of the fatty acid binding protein family are differentiation factors for the mammary gland. J Cell Biol (1994) 1.01
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol (1999) 1.01
The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol (2012) 1.01
The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol (2000) 1.01
Endothelial cells of the human microvasculature express epidermal fatty acid-binding protein. Circ Res (1997) 0.99
Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer (2003) 0.99
Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res (1984) 0.99
The binding affinity of fatty acid-binding proteins from human, pig and rat liver for different fluorescent fatty acids and other ligands. Int J Biochem (1989) 0.99
[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer (2008) 0.98
Purification and characterization of fatty-acid-binding proteins from rat heart and liver. Biochim Biophys Acta (1985) 0.98
The composition of the cell wall of Lactobacillius bifidus var. pennsylvanicus. Arch Biochem Biophys (1965) 0.98
Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep (1986) 0.98
Comparison of the phospholipid composition of Bifidobacterium and Lactobacillus strains. J Bacteriol (1971) 0.98
Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol (2002) 0.98
Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol (1995) 0.98
Attachment of glycosaminoglycans to collagenous matrices modulates the tissue response in rats. Biomaterials (2000) 0.97
Preparation and evaluation of molecularly-defined collagen-elastin-glycosaminoglycan scaffolds for tissue engineering. Biomaterials (2003) 0.97
Myotonic dystrophy protein kinase is involved in the modulation of the Ca2+ homeostasis in skeletal muscle cells. J Clin Invest (1997) 0.97
Structure of the lipoteichoic acids from Bifidobacterium bifidum spp. pennsylvanicum. Biochim Biophys Acta (1984) 0.97